4640-69-1

Usage

Uses

Used in Pharmaceutical Industry:
3,4-DIMETHOXYBENZOYLACETONITRILE is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications. Its role in the creation of heterocyclic compounds makes it valuable in the production of a wide range of therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-DIMETHOXYBENZOYLACETONITRILE is utilized as an intermediate in the synthesis of various agrochemicals, including pesticides and herbicides. Its involvement in the production of these chemicals helps to improve agricultural productivity and crop protection.
Used in Research and Development:
3,4-DIMETHOXYBENZOYLACETONITRILE is used as a reagent and precursor in research and development for the synthesis of biologically active molecules. Its application in this field aids scientists in discovering and creating new compounds with potential applications in medicine, agriculture, and other industries.
Used in the Synthesis of Heterocyclic Compounds:
3,4-DIMETHOXYBENZOYLACETONITRILE is used as a building block for the preparation of diverse heterocyclic compounds. These compounds are important in various chemical and pharmaceutical applications, making 3,4-DIMETHOXYBENZOYLACETONITRILE a valuable component in the synthesis of complex organic molecules.

InChI:InChI=1/C11H11NO3/c1-14-10-4-3-8(7-11(10)15-2)9(13)5-6-12/h3-4,7H,5H2,1-2H3

Upstream product

• 3943-77-9 ethyl veratrate 
• 2150-38-1 methyl 3,4-dimethoxybenzoate 
• 75-05-8 acetonitrile 
• 1116-98-9 cyanoacetic acid tert-butyl ester 
• 2859-78-1 4-Bromoveratrole 
• 82102-37-2 9-methyl-9H-fluorene-9-carbonyl chloride 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 3535-37-3 3,4-dimethoxybenzoic acid chloride 
• 151-50-8 potassium cyanide 

Downstream Products

• 179327-28-7 (2-amino-6-ethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-3-yl)-(3,4-dimethoxy-phenyl)-methanone 
• 179327-24-3 2-amino-6-benzyl-3-(3,4-dimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine 
• 199102-72-2 2-amino-7-benzyloxycarbonyl-3-(3,4-dimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-b]pyridine 
• 199102-52-8 2-amino-6-benzoyl-3-(3,4-dimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine 
• 208519-08-8 3-(3,4-dimethoxyphenyl)-2H-pyrazol-5-amine 
• 199102-71-1 ω-cyano-4-isopropoxy-3-methoxyacetophenone 
• 1029095-72-4 (Z)-2-cyano-1-(3,4-dimethoxyphenyl)vinyl trifluoromethanesulfonate 
• 1401219-51-9 N-(3-(3,4-dimethoxyphenyl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1476782-09-8 5-(3,4-dimethoxyphenyl)furan-2,3,4-tricarbonitrile 
• 1082912-26-2 (2-amino-4-phenylthiophen-3-yl)(3,4-dimethoxyphenyl)methanone 
• 1265048-93-8 2-(3,4-dimethoxybenzoyl)-3-phenylbut-2-enenitrile 
• 199102-01-7 ethyl 6-(4-chlorobenzoyl)-2-diethylaminomethyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:4,5-c']dipyridine-3-carboxylate 
• 199102-06-2 ethyl 8-benzyloxycarbonyl-2-diethylaminomethyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-b']dipyridine-3-carboxylate 

Relevant academic research and scientific papers

Deadly KCN and pricey metal free track for accessing β-ketonitriles employing mild reaction conditions

A one pot synthesis of β-ketonitriles from readily accessible 3-chloropropenals using economically benign iodine, aqueous ammonia and sodium hydroxide solution, employing mild reaction conditions have been described. This report presents a convenient, inexpensive, highly toxic-matter-free and eco-friendly approach for β-ketonitriles.

Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV4-11 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML.

3,5-Diaryl-1H-pyrazolo[3,4-b]pyridines as potent tubulin polymerization inhibitors: Rational design, synthesis and biological evaluation

A series of novel 3,5-diaryl-1H-pyrazolo[3,4-b]pyridines as tubulin polymerization inhibitors targeting the colchicine site were designed via ring tethering strategy, which was supported by conformational analysis. The general, chemically unstable and rot

Palladium-Catalyzed Carbonylative α-Arylation of tert -Butyl Cyanoacetate with (Hetero)aryl Bromides

A three-component coupling protocol has been developed for the generation of 3-oxo-3-(hetero)arylpropanenitriles via a carbonylative palladium-catalyzed α-arylation of tert-butyl 2-cyanoacetates with (hetero)aryl bromides followed by an acid-mediated decarboxylation step. Through the combination of only a stoichiometric loading of carbon monoxide and mild basic reaction conditions such as MgCl2 and dicyclohexylmethylamine for the deprotonation step, an excellent functional group tolerance was ensured for the methodology. Through the use of 13C-labeled carbon monoxide generated from 13COgen, the corresponding 13C-isotopically labeled β-ketonitriles were obtained, and these products could subsequently be converted into cyanoalkynes and 3-cyanobenzofurans with site specific 13C-isotope labeling. (Chemical Equation Presented).

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

Stereoselective synthesis of 3,3-diarylacrylonitriles as tubulin polymerization inhibitors

(Chemical Equation Presented) A series of 3,3-diarylacrylonitriles were synthesized stereo-selectively as tubulin polymerization inhibitors for potential use in cancer chemotherapy. This synthetic route features stannylcupration and palladium-catalyzed St

Aminopyrazole derivatives

The present invention relates to a compound represented by the general formula [I]: wherein Ar1 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alke

Thienodipyridine derivatives, production and use thereof

A compound of the formula (I): wherein R is hydrogen or C2-6alkanoyl; X is halogen; and ring A is benzene ring which is optionally substituted by 1 to 4 substituents selected from {circle around (1)} halogen, {circle around (2)} hydroxy, {circl

Thienopyridine derivatives and their use

PCT No. PCT/JP97/01413 Sec. 371 Date Jun. 26, 1997 Sec. 102(e) Date Jun. 26, 1997 PCT Filed Apr. 23, 1997 PCT Pub. No. WO97/40050 PCT Pub. Date Oct. 30, 1997There is disclosed a compound of the formula (A): wherein W is C-G or C-G' (G is optionally esterified carboxyl; and G' is halogen); X is oxygen, optionally oxidized sulfur or -(CH2)q- (q is 0 to 5); R is optionally substituted amino or heterocyclic group; the ring B is optionally substituted nitrogen-containing 5- to 7-membered ring; L is hydrogen, optionally substituted hydrocarbon residue, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl provided that, when W is C-G, L is hydrogen, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted alkoxycarbonyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl; n is 0 or 1; the ring A may have a substituent. A process for producing the compound (A) and a pharmaceutical composition containing the compound (A) are also disclosed. The pharmaceutical composition is useful for an anti-inflammatory drug, particularly, a drug for preventing or treating arthritis, a drug for inhibiting bone resorption, immunosuppressant or the like.

Urea derivatives

The present invention relates to a compound represented by the general formula [I]: STR1 wherein A represents a nitrogen atom or a group represented by C--R5 ; Ar1 represents an aryl group which may have a substituent selected from t